Quarterly Result27 May 2026, 04:30 pm
Concord Drugs Approves FY26 Financial Results
AI Summary
Concord Drugs Ltd's board meeting on May 27, 2026, approved the standalone and consolidated financial results for the quarter and year ended March 31, 2026. The results, along with the auditor's report, are available on the company's website and the BSE Limited website. The company's revenue from operations increased to ₹7,873.68 lakhs in FY26 from ₹4,524.46 lakhs in FY25. Profit after tax stood at ₹105.50 lakhs in FY26 compared to ₹33.62 lakhs in FY25.
Key Highlights
- Concord Drugs board approved FY26 standalone and consolidated financial results.
- FY26 revenue from operations increased to ₹7,873.68 lakhs.
- Profit after tax for FY26 was ₹105.50 lakhs.
- Auditors Report was noted by the board.
Price Impact
More from CONCORD
More in Quarterly Result